Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

DNLI

Denali Therapeutics Inc

Nov 27 • 04:00PM ET

25.16

Dollar change +0.48
Percentage change 1.94	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: IWM VTI VB VXF VBK XBI IBB IWO VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.76	Insider Own	13.45%	Shs Outstand	138.39M	Perf Week	3.03%
Market Cap	3.69B	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-1.16%	Shs Float	124.57M	Perf Month	-8.41%
Income	-427.49M	PEG	-	EPS next Q	-0.82	Inst Own	88.60%	Short Float	5.70%	Perf Quarter	3.11%
Sales	0.00M	P/S	-	EPS this Y	-162.14%	Inst Trans	6.24%	Short Ratio	7.95	Perf Half Y	36.29%
Book/sh	9.17	P/B	2.74	EPS next Y	-2.63%	ROA	-31.77%	Short Interest	7.10M	Perf Year	37.34%
Cash/sh	5.70	P/C	4.41	EPS next 5Y	-	ROE	-35.09%	52W Range	14.56 - 33.33	Perf YTD	17.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.99%	ROI	-31.36%	52W High	-24.51%	Beta	1.35
Dividend TTM	-	Quick Ratio	9.98	Sales past 5Y	264.19%	Gross Margin	-570.72%	52W Low	72.80%	ATR (14)	1.31
Dividend Ex-Date	-	Current Ratio	9.98	EPS Y/Y TTM	-197.15%	Oper. Margin	0.00%	RSI (14)	42.38	Volatility	3.69% 5.34%
Employees	445	Debt/Eq	0.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.35	Target Price	42.08
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	12.36%	Payout	-	Rel Volume	0.65	Prev Close	24.68
Sales Surprise	-100.00%	EPS Surprise	-5.86%	Sales Q/Q	-100.00%	Earnings	Nov 06 AMC	Avg Volume	893.19K	Price	25.16
SMA20	-6.67%	SMA50	-8.60%	SMA200	10.74%	Trades		Volume	577,772	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85
Sep-01-21	Initiated	SMBC Nikko	Outperform	$78
May-18-21	Initiated	UBS	Buy	$70
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$80 → $95
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$105
Nov-11-20	Reiterated	H.C. Wainwright	Buy	$65 → $80
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight	$35

Show Previous Ratings

Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
08:00AM	Loading…
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
07:00AM	Loading…
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
08:30AM	Loading…
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%
Feb-27-24 08:31AM	Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +38.25%
08:05AM	Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Denali Therapeutics Announces $500 million Private Placement Equity Financing (GlobeNewswire)
06:53AM	Denali, fresh off study setback, gets $500M lift (BioPharma Dive)
Feb-16-24 08:39AM	UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal (Reuters) -7.30%
08:22AM	Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (Reuters)
07:13AM	ALS drug from Denali, Sanofi falls short in mid-stage study (BioPharma Dive)
Feb-07-24 08:00AM	Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium (GlobeNewswire)
Feb-01-24 08:00AM	Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium (GlobeNewswire)
Jan-31-24 11:04PM	Baillie Gifford Reduces Stake in Denali Therapeutics Inc (GuruFocus.com)
Jan-26-24 10:00AM	Denali's (DNLI) Pipeline Progresses Despite Stiff Competition (Zacks)
Jan-11-24 01:11PM	40 Cities with the Lowest Life Expectancy in the US (Insider Monkey)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 08:00AM	Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire) +5.27%
06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace)
Dec-22-23 06:22AM	40 Cities with the Highest Life Expectancy in the US (Insider Monkey)
Dec-21-23 09:55AM	Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect? (Zacks)
Dec-07-23 11:31AM	Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report? (Zacks)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
09:55AM	Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High? (Zacks)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) -5.11%
Nov-07-23 05:50PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-06-23 09:55AM	Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet (Zacks)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-06-23 04:41AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains? (Zacks)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire)
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report? (Zacks)
Aug-30-23 08:30AM	Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-11-23 11:36AM	20 Countries that Have the Most Billionaires Per Capita (Insider Monkey)
Aug-10-23 12:02PM	Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues (Zacks)
06:03AM	Pinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right Now (Simply Wall St.)
Aug-08-23 06:05PM	Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-29-23 05:13AM	Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now (InvestorPlace)
Jun-27-23 02:23PM	In the wake of Denali Therapeutics Inc.'s (NASDAQ:DNLI) latest US$402m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Jun-26-23 10:00AM	Salt Lake City Ups the Ante in Bid to Become a Fintech Hub (The Wall Street Journal)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
06:00AM	Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs (PR Newswire)
Jun-20-23 04:20PM	Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker (Benzinga)
07:00AM	Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) (GlobeNewswire)
Jun-09-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? (Zacks)
Jun-08-23 11:30AM	Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report? (Zacks)
Jun-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report? (Zacks)
Jun-05-23 06:15PM	Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure (Benzinga)
May-31-23 01:30PM	Denali Therapeutics (NASDAQ:DNLI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire) -8.49%
May-15-23 04:31PM	Why Shares of Denali Therapeutics Are Up Monday (Motley Fool) +14.52%
May-09-23 01:24PM	Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus (Zacks)
May-08-23 05:15PM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 01:21PM	Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 40% Undervaluation? (Simply Wall St.)
May-01-23 10:00AM	Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline (Zacks)
Apr-27-23 10:02AM	Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-14-23 07:03AM	Denali Therapeutics' (NASDAQ:DNLI) investors will be pleased with their 28% return over the last five years (Simply Wall St.)
Apr-12-23 08:00AM	Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta (GlobeNewswire)
Apr-10-23 08:00AM	Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-29-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report? (Zacks)
Mar-04-23 07:35AM	The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically (Simply Wall St.)
Feb-28-23 09:01AM	Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus (Zacks)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ho Carole	Chief Medical Officer	Nov 25 '24	Option Exercise	0.68	17,845	12,135	136,655	Nov 27 04:44 PM
Schuth Alexander O.	COFO and Secretary	Nov 22 '24	Option Exercise	0.68	20,516	13,951	198,582	Nov 26 05:19 PM
Schenkein David P	Director	Nov 11 '24	Option Exercise	18.00	47,165	848,970	68,661	Nov 13 04:18 PM
Schenkein David P	Director	Nov 11 '24	Sale	32.51	59,441	1,932,665	9,220	Nov 13 04:18 PM
Schuth Alexander O.	COFO and Secretary	Nov 07 '24	Option Exercise	5.28	15,558	82,146	193,624	Nov 12 04:44 PM
Schuth Alexander O.	COFO and Secretary	Nov 07 '24	Sale	29.91	15,558	465,286	178,066	Nov 12 04:44 PM
SATO VICKI L	Director	Nov 07 '24	Sale	30.00	1,020	30,600	111,056	Nov 12 04:43 PM
DAVID SCHENKEIN	Director	Nov 11 '24	Proposed Sale	31.35	59,441	1,863,475		Nov 12 07:47 AM
ALEXANDER SCHUTH	Officer	Nov 07 '24	Proposed Sale	29.55	15,558	459,739		Nov 07 04:39 PM
SATO VICKI L	Director	Nov 01 '24	Sale	27.07	3,080	83,376	112,076	Nov 05 04:21 PM
Watts Ryan J.	President and CEO	Oct 18 '24	Option Exercise	0.68	40,000	27,200	275,807	Oct 22 04:30 PM
Watts Ryan J.	President and CEO	Oct 18 '24	Sale	27.69	40,000	1,107,600	235,807	Oct 22 04:30 PM
RYAN WATTS	Director	Oct 18 '24	Proposed Sale	27.42	40,000	1,096,800		Oct 18 04:19 PM
Krognes Steve E.	Director	Sep 30 '24	Sale	29.03	30,000	870,900	29,096	Oct 02 04:37 PM
STEVE KROGNES	Director	Sep 30 '24	Proposed Sale	29.43	30,000	882,900		Sep 30 04:25 PM
SATO VICKI L	Director	Sep 13 '24	Sale	30.00	1,020	30,600	115,156	Sep 16 04:17 PM
VICKI LEE SATO	Director	Sep 13 '24	Proposed Sale	27.96	6,160	172,234		Sep 13 04:25 PM
SATO VICKI L	Director	Sep 03 '24	Sale	25.00	3,080	77,007	116,176	Sep 04 06:26 PM
Watts Ryan J.	President and CEO	Aug 20 '24	Sale	23.79	2,260	53,765	235,807	Aug 22 04:16 PM
Krognes Steve E.	Director	Aug 20 '24	Sale	23.79	1,727	41,085	32,677	Aug 22 04:15 PM
Schuth Alexander O.	COFO and Secretary	Aug 20 '24	Sale	23.65	5,806	137,286	180,613	Aug 22 04:14 PM
Schuth Alexander O.	COFO and Secretary	Aug 21 '24	Sale	24.78	2,547	63,115	178,066	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 21 '24	Sale	24.57	20,005	491,571	118,810	Aug 22 04:14 PM
Ho Carole	Chief Medical Officer	Aug 20 '24	Sale	23.79	2,453	58,357	138,815	Aug 22 04:14 PM
CAROLE HO	Officer	Aug 21 '24	Proposed Sale	23.65	20,005	473,118		Aug 21 04:42 PM
ALEXANDER SCHUTH	Officer	Aug 21 '24	Proposed Sale	23.65	2,547	60,237		Aug 21 04:40 PM
Krognes Steve E.	Director	Aug 20 '24	Proposed Sale	23.79	1,727	41,085		Aug 20 08:09 PM
Schuth Alexander O.	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,357		Aug 20 08:09 PM
Watts Ryan J.	Director	Aug 20 '24	Proposed Sale	23.79	2,260	53,765		Aug 20 08:08 PM
Ho Carole	Officer	Aug 20 '24	Proposed Sale	23.79	2,453	58,356		Aug 20 08:08 PM
ALEXANDER SCHUTH	Officer	Aug 20 '24	Proposed Sale	23.95	3,353	80,304		Aug 20 04:27 PM
Schuth Alexander O.	COFO and Secretary	Aug 13 '24	Sale	22.89	2,272	52,006	186,419	Aug 15 04:10 PM
Ho Carole	Chief Medical Officer	Aug 13 '24	Sale	22.89	2,337	53,494	141,268	Aug 15 04:09 PM
Schuth Alexander O.	Officer	Aug 13 '24	Proposed Sale	22.89	2,272	52,006		Aug 13 08:37 PM
Ho Carole	Officer	Aug 13 '24	Proposed Sale	22.89	2,337	53,494		Aug 13 08:36 PM
Krognes Steve E.	Director	Jul 01 '24	Sale	22.12	30,000	663,668	34,404	Jul 03 09:13 PM
Krognes Steve E.	Director	Jun 13 '24	Sale	21.79	688	14,992	52,620	Jul 03 09:13 PM
SATO VICKI L	Director	Jul 01 '24	Sale	22.14	3,080	68,204	119,256	Jul 03 09:13 PM
Cook Jennifer E.	Director	Jun 06 '24	Sale	21.73	1,458	31,682	20,038	Jun 10 08:06 PM
SATO VICKI L	Director	May 15 '24	Sale	20.39	1,674	34,133	116,369	May 17 04:28 PM
SATO VICKI L	Director	Apr 15 '24	Sale	18.29	1,666	30,471	118,043	Apr 17 05:14 PM
Krognes Steve E.	Director	Apr 01 '24	Sale	20.50	92,500	1,896,250	47,341	Apr 02 06:07 PM
SATO VICKI L	Director	Mar 15 '24	Sale	20.10	1,666	33,487	119,709	Mar 19 04:27 PM
SATO VICKI L	Director	Feb 15 '24	Sale	18.37	1,666	30,604	121,375	Feb 20 05:38 PM
Krognes Steve E.	Director	Feb 13 '24	Sale	17.29	2,750	47,548	139,841	Feb 15 09:16 PM
Watts Ryan J.	President and CEO	Feb 13 '24	Sale	17.29	9,589	165,794	238,067	Feb 15 09:15 PM
Ho Carole	Chief Medical Officer	Feb 13 '24	Sale	17.29	2,784	48,135	145,010	Feb 15 09:14 PM
Ho Carole	Chief Medical Officer	Feb 14 '24	Sale	17.79	1,405	24,995	143,605	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 14 '24	Sale	17.66	20,128	355,460	187,341	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 13 '24	Sale	17.29	2,716	46,960	207,469	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 08 '24	Option Exercise	0.68	50,000	34,000	210,185	Feb 12 04:48 PM
SATO VICKI L	Director	Jan 16 '24	Sale	18.42	1,666	30,688	123,041	Jan 18 06:26 PM
Ho Carole	Chief Medical Officer	Jan 10 '24	Sale	19.02	4,668	88,785	147,794	Jan 12 08:18 PM
Watts Ryan J.	President and CEO	Jan 09 '24	Sale	19.78	7,818	154,640	2,268,363	Jan 11 05:28 PM
Ho Carole	Chief Medical Officer	Jan 05 '24	Sale	19.43	9,972	193,756	198,777	Jan 09 07:35 PM
Krognes Steve E.	Director	Jan 05 '24	Sale	19.43	3,208	62,331	142,591	Jan 09 07:34 PM
Schuth Alexander O.	COFO and Secretary	Jan 05 '24	Sale	19.43	9,972	193,756	539,307	Jan 09 07:34 PM
Watts Ryan J.	President and CEO	Jan 05 '24	Sale	19.43	17,483	339,695	2,276,181	Jan 09 07:33 PM
SATO VICKI L	Director	Dec 15 '23	Sale	23.39	1,666	38,968	124,707	Dec 18 07:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNLI

Denali Therapeutics Inc

Upgrade your FINVIZ experience